KRAS and pancreatic neoplasm: Pancreatic cancers without KRAS mutations (about 10% of PDAC) show wild type RAS activation via upstream signaling through receptor tyrosine kinases, including epidermal growth factor receptor (EGFR), which is also required in KRASG12D-driven PDAC [16,19,20].